Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06174220 | Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | PHASE2 | RECRUITING | 120 | — | — | Mar 21, 2025 | Jul 1, 2027 | Mar 12, 2026 | 17 | Canada |
Change in mean PVC count per 24 hours on 7-day Holter
| Arm | Type | Description |
|---|---|---|
| Tideglusib | ACTIVE_COMPARATOR | Randomization to Tideglusib 1g po daily or matching placebo |
| Placebo | PLACEBO_COMPARATOR | Randomization to matching placebo 1g po daily |
| Name | Type | Description |
|---|---|---|
| Tideglusib | DRUG | Tideglusib 1g po daily |
| Placebo | DRUG | Matching placebo 1g po daily |
Inclusion Criteria: * A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\*) rare variant OR the TMEM43-p.S358L variant \*JUP carriers must be homozygous or compound heterozygous * Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor * Clinical ACM di...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | 3 | PHASE1 | LX2020 |